Enclomiphene

Summary

Enclomiphene (CHEMBL954) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including obesity disorder and hypogonadism.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 28
• Chemistry: 406 Da · C26H28ClNO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL954
Name	Enclomiphene
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	1548953
Molecular formula	C26H28ClNO
Molecular weight	406
InChIKey	GKIRPKYJQBWNGO-OCEACIFDSA-N

SMILES: CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\C2=CC=CC=C2)/Cl)/C3=CC=CC=C3

IUPAC name: 2-[4-[(E)-2-chloro-1,2-diphenylethenyl]phenoxy]-N,N-diethylethanamine

Also known as: Cisclomiphene, Clomiphene trans-form, Enclomifene, Enclomifeno, Enclomiphene, ICI-46476, ISOMER B, ISOMER-B, RMI 16,289, Rmi-16,289, RMI-16289, SID50085975

Parent form; salt/anhydrous children: CHEMBL1200667

Patent coverage: 4,891 distinct patent families (17,907 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 33 (assay-derived). Sample: Nuclear receptor ROR-gamma, 4’-phosphopantetheinyl transferase ffp, Histone-lysine N-methyltransferase 2A, Muscarinic acetylcholine receptor M4, Receptor tyrosine-protein kinase erbB-2, 5-hydroxytryptamine receptor 2B, Tyrosine-protein kinase Fyn, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Beta-lactamase, Epidermal growth factor receptor, Muscarinic acetylcholine receptor M5, Estrogen receptor, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Prostaglandin G/H synthase 1, Sodium-dependent noradrenaline transporter, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C.

Bioactivity

ChEMBL activities: 53 potent at pChembl ≥ 5 of 56 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
EBP	9	Ki	1	nM	CHEMBL_ACT_1483726
ESR1	8.88	Ki	1.3	nM	CHEMBL_ACT_7706037
ESR1	8.34	IC50	4.56	nM	CHEMBL_ACT_7706036
SIGMAR1	8.1	Ki	8	nM	CHEMBL_ACT_1483727
SIGMAR1	7.92	Ki	12	nM	CHEMBL_ACT_7708237
SIGMAR1	7.54	IC50	29	nM	CHEMBL_ACT_7708236
P32352	6.8	Ki	160	nM	CHEMBL_ACT_1483728
ADRA2C	6.67	Ki	215	nM	CHEMBL_ACT_7703926
CHRM4	6.64	Ki	230	nM	CHEMBL_ACT_7706093
SLC6A4	6.47	Ki	339	nM	CHEMBL_ACT_7708235
ADRA2A	6.46	Ki	351	nM	CHEMBL_ACT_7703922
PTGS1	6.46	IC50	346	nM	CHEMBL_ACT_7706006
CHRM1	6.41	Ki	392	nM	CHEMBL_ACT_7706087
CHRM3	6.36	Ki	439	nM	CHEMBL_ACT_7706091
DRD3	6.35	Ki	448	nM	CHEMBL_ACT_7706029
SLC6A3	6.21	Ki	623	nM	CHEMBL_ACT_7706033
SLC6A4	6.2	IC50	638	nM	CHEMBL_ACT_7708234
HTR2C	6.18	Ki	666	nM	CHEMBL_ACT_7708227
P00811	6.15	Potency	707.9	nM	CHEMBL_ACT_4697566
HTR6	6.15	Ki	707	nM	CHEMBL_ACT_7708233
ADRA2B	6.14	Ki	721	nM	CHEMBL_ACT_7703924
SLC6A3	6.11	IC50	784	nM	CHEMBL_ACT_7706032
SLC6A2	6.07	Ki	855	nM	CHEMBL_ACT_7703934
SLC6A2	6.06	IC50	862	nM	CHEMBL_ACT_7703933
HTR2B	6.06	Ki	867	nM	CHEMBL_ACT_7708225
ADRA2A	6.03	IC50	936	nM	CHEMBL_ACT_7703921
HTR2A	6.03	Ki	945	nM	CHEMBL_ACT_7708223
EGFR	5.98	IC50	1050	nM	CHEMBL_ACT_7708206
CHRM5	5.9	Ki	1272	nM	CHEMBL_ACT_7706095
HTR2C	5.9	IC50	1272	nM	CHEMBL_ACT_7708226
CHRM2	5.89	Ki	1290	nM	CHEMBL_ACT_7706089
DRD3	5.88	IC50	1319	nM	CHEMBL_ACT_7706028
HTR2B	5.87	IC50	1363	nM	CHEMBL_ACT_7708224
ADRA2C	5.83	IC50	1482	nM	CHEMBL_ACT_7703925
HTR6	5.82	IC50	1522	nM	CHEMBL_ACT_7708232
TACR2	5.82	Ki	1508	nM	CHEMBL_ACT_7708245
ADRA2B	5.8	IC50	1578	nM	CHEMBL_ACT_7703923
CHRM1	5.79	IC50	1628	nM	CHEMBL_ACT_7706086
CHRM4	5.78	IC50	1651	nM	CHEMBL_ACT_7706092
ERBB2	5.78	IC50	1669	nM	CHEMBL_ACT_7708210
CHRM5	5.75	IC50	1771	nM	CHEMBL_ACT_7706094
CHRM3	5.68	IC50	2071	nM	CHEMBL_ACT_7706090
P15823	5.6	Ki	2529	nM	CHEMBL_ACT_7703918
FYN	5.6	IC50	2513	nM	CHEMBL_ACT_7708208
ADORA3	5.52	Ki	3024	nM	CHEMBL_ACT_7703912
HTR2A	5.48	IC50	3308	nM	CHEMBL_ACT_7708222
CHRM2	5.44	IC50	3628	nM	CHEMBL_ACT_7706088
ADRB3	5.37	Ki	4254	nM	CHEMBL_ACT_7703932
P15823	5.34	IC50	4569	nM	CHEMBL_ACT_7703917
TACR2	5.34	IC50	4525	nM	CHEMBL_ACT_7708244
ADORA3	5.27	IC50	5350	nM	CHEMBL_ACT_7703911
ADRB3	5.25	IC50	5673	nM	CHEMBL_ACT_7703931
CYP2D6	5	IC50	10000	nM	CHEMBL_ACT_7706018

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
obesity disorder	2	MONDO:0011122	EFO:0001073
hypogonadism	2	MONDO:0002146	MONDO:0002146

Clinical trials

Total trials: 28.

Phase distribution

Phase	Trials
Not specified	12
PHASE4	10
PHASE2	5
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07462065	PHASE4	RECRUITING	Effect Clomiphene vs Clomiphene Along With Pioglitazone on Ovarian Stimulation Rate
NCT00795808	PHASE4	COMPLETED	PCOSMIC Trial - PolyCystic Ovary Syndrome, Metformin for Infertility With Clomiphene
NCT01577199	PHASE4	WITHDRAWN	RCT of Low-dose Clomiphene vs. High Dose Gonadotropin Protocol for IVF Poor Responders
NCT02638285	PHASE4	COMPLETED	Pregnancy Rate by HCG Administration Versus Urinary LH Surge Method in Patients Undergoing IUI
NCT02690870	PHASE4	UNKNOWN	Tamoxifen and Clomiphene Citrate in Mild Stimulation IVF
NCT02802865	PHASE4	COMPLETED	Combined Letrozole and Clomid in Women With Infertility and PCOS
NCT03400722	PHASE4	UNKNOWN	Double Ovarian Stimulation as Accumulation Strategy for Older Infertile Patients With Suboptimal Ovarian Response
NCT03989024	PHASE4	UNKNOWN	Pulsatile Gonadotropin-releasing Hormone for Infertility in Non-obese Patients With Polycystic Ovary Syndrome
NCT04010942	PHASE4	COMPLETED	Vitamin D for Polycystic Ovary Syndrome Clomiphene Resistant Women
NCT06178523	PHASE4	COMPLETED	Cost-effective Treatment of Unexplained Infertility
NCT01155518	PHASE2	TERMINATED	Hypogonadism in Young Men With Type 2 Diabetes
NCT01904734	PHASE2	COMPLETED	Clomid in Men With Low Testosterone With and Without Prior Treatment
NCT02651688	PHASE2	COMPLETED	A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene
NCT02663830	PHASE2	COMPLETED	The Effect of Sildenafil Citrate on the Success Rate of Ovulation Induction Using Clomiphene
NCT03245827	PHASE2	TERMINATED	Hypogonadotropic Hypogonadism in Obese Young Males
NCT01289756	PHASE1	COMPLETED	Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene
NCT07568574	Not specified	ENROLLING_BY_INVITATION	Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes
NCT01291056	Not specified	COMPLETED	Differential Effects of Clomiphene Citrate in Women Undergoing Superovulation
NCT01607320	Not specified	TERMINATED	Efficacy Study of Raloxifene to Induce Ovulation in Polycystic Ovarian Syndrome
NCT01679574	Not specified	COMPLETED	Letrozole or Combined Clomiphene Citrate Metformin as a First Line Treatment in Women With Polycystic Ovarian Syndrome
NCT01953796	Not specified	COMPLETED	Clomiphene Stair-Step Protocol for Ovulation Induction in Women With Polycystic Ovarian Syndrome
NCT02137265	Not specified	WITHDRAWN	Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism
NCT02294773	Not specified	COMPLETED	Study Evaluating the Timing of Intrauterine Insemination in Relation to Positive Home Ovulation Prediction Kit
NCT02377479	Not specified	WITHDRAWN	Endocrinology Profile in Patients Undergoing Clomiphene, Letrozole, and Combination Clomiphene and Letrozole Cycles
NCT02647424	Not specified	UNKNOWN	A Comparison of Letrozole and Clomifene Citrate
NCT02775877	Not specified	UNKNOWN	Letrozole and Sequential Clomiphene to Improve the Outcome of Embryo Transfer
NCT05866068	Not specified	UNKNOWN	Use of Clomiphene Citrate as an Inhibitor of Ovulation in an Oocyte Cryopreservation Cycle
NCT07398924	Not specified	COMPLETED	Vaginal Estradiol and Oral Guaifenesin in Clomiphene Ovulation Induction

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).